Evidence map›Paper›PMID 24453980›Full record

ArticlePLoS pathogens2014

TREM-1 deficiency can attenuate disease severity without affecting pathogen clearance.

Benjamin Weber, Steffen Schuster, Daniel Zysset, Silvia Rihs, Nina Dickgreber, Christian Schürch, Carsten Riether, Mark Siegrist, Christoph Schneider, Helga Pawelski and 12 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed, 1 pooled it
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 1 synthesis or guideline pooled it, 131 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. The biology of TREM receptors.Nature reviews. Immunology · 2023
    Review

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 3 institutions in 1 country.

Benjamin WeberDivision of Experimental Pathology, Institute of Pathology, University of Bern, Bern, Switzerland.
Steffen SchusterDepartment of Biochemistry, University of Lausanne, Epalinges, Switzerland.
Daniel ZyssetDivision of Experimental Pathology, Institute of Pathology, University of Bern, Bern, Switzerland.
Silvia RihsDivision of Experimental Pathology, Institute of Pathology, University of Bern, Bern, Switzerland.
Nina DickgreberDivision of Experimental Pathology, Institute of Pathology, University of Bern, Bern, Switzerland.
Christian SchürchDivision of Experimental Pathology, Institute of Pathology, University of Bern, Bern, Switzerland ; Department of Clinical Research, University of Bern, Bern, Switzerland.
Carsten RietherDepartment of Clinical Research, University of Bern, Bern, Switzerland.
Mark SiegristDepartment of Clinical Research, University of Bern, Bern, Switzerland.
Christoph SchneiderInstitute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland.
Helga PawelskiInstitute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland.
Ursina GurzelerInstitute of Pharmacology, University of Bern, Bern, Switzerland.
Pascal ZiltenerInstitute of Microbiology, ETH Zurich, Zurich, Switzerland.
Vera GenitschDivision of Experimental Pathology, Institute of Pathology, University of Bern, Bern, Switzerland.
Fabienne Tacchini-CottierDepartment of Biochemistry, University of Lausanne, Epalinges, Switzerland.
Adrian OchsenbeinDepartment of Clinical Research, University of Bern, Bern, Switzerland ; Department of Medical Oncology, University of Bern, Bern, Switzerland.
Willy HofstetterDepartment of Clinical Research, University of Bern, Bern, Switzerland.
Manfred KopfInstitute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland.
Thomas KaufmannInstitute of Pharmacology, University of Bern, Bern, Switzerland.
Annette OxeniusInstitute of Microbiology, ETH Zurich, Zurich, Switzerland.
Walter ReithDepartment of Pathology and Immunology, Centre Medical Universitaire, Geneva, Switzerland.
Leslie SaurerDivision of Experimental Pathology, Institute of Pathology, University of Bern, Bern, Switzerland.
Christoph MuellerDivision of Experimental Pathology, Institute of Pathology, University of Bern, Bern, Switzerland.
University of Bern · CHETH Zurich · CHUniversity of Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triggering receptor expressed on myeloid cells-1 (TREM-1) is a potent amplifier of pro-inflammatory innate immune reactions. While TREM-1-amplified responses likely aid an improved detection and elimination of pathogens, excessive production of cytokines and oxygen radicals can also severely harm the host. Studies addressing the pathogenic role of TREM-1 during endotoxin-induced shock or microbial sepsis have so far mostly relied on the administration of TREM-1 fusion proteins or peptides representing part of the extracellular domain of TREM-1. However, binding of these agents to the yet unidentified TREM-1 ligand could also impact signaling through alternative receptors. More importantly, controversial results have been obtained regarding the requirement of TREM-1 for microbial control. To unambiguously investigate the role of TREM-1 in homeostasis and disease, we have generated mice deficient in Trem1. Trem1(-/-) mice are viable, fertile and show no altered hematopoietic compartment. In CD4(+) T cell- and dextran sodium sulfate-induced models of colitis, Trem1(-/-) mice displayed significantly attenuated disease that was associated with reduced inflammatory infiltrates and diminished expression of pro-inflammatory cytokines. Trem1(-/-) mice also exhibited reduced neutrophilic infiltration and decreased lesion size upon infection with Leishmania major. Furthermore, reduced morbidity was observed for influenza virus-infected Trem1(-/-) mice. Importantly, while immune-associated pathologies were significantly reduced, Trem1(-/-) mice were equally capable of controlling infections with L. major, influenza virus, but also Legionella pneumophila as Trem1(+/+) controls. Our results not only demonstrate an unanticipated pathogenic impact of TREM-1 during a viral and parasitic infection, but also indicate that therapeutic blocking of TREM-1 in distinct inflammatory disorders holds considerable promise by blunting excessive inflammation while preserving the capacity for microbial control.

Indexed as

AnimalsCD4-Positive T-LymphocytesColitisDisease Models, AnimalInfluenza A virusLegionella pneumophilaLegionnaires' DiseaseLeishmania majorLeishmaniasis, CutaneousMembrane GlycoproteinsMiceMice, KnockoutOrthomyxoviridae InfectionsReceptors, ImmunologicTriggering Receptor Expressed on Myeloid Cells-1Membrane GlycoproteinsReceptors, ImmunologicTREM1 protein, mouseTriggering Receptor Expressed on Myeloid Cells-1

Identifiers

PMID24453980
PMCPMC3894224
OpenAlexW2080678175

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.